Rani Therapeutics (RANI)
(Delayed Data from NSDQ)
$3.70 USD
+0.11 (3.06%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.70 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Rani Therapeutics Holdings, Inc. [RANI]
Reports for Purchase
Showing records 21 - 40 ( 44 total )
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Q1:23: Continuing to Progress Through Execution Year, Catalysts Ahead in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY22: Execution Year Setting Up for Multiple Value-Driving Catalysts in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
2022 Financial Results; Pipeline Continues to Advance; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Celltrion Deal Secures Access to Stelara Biosimilar for Autoimmune RaniPill Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
FDA Meeting Suggests 505(b)(2) Pathway for RT-102; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Favorable Repeat-Dose Data Demonstrated with RaniPill; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Dose, Deploy, Repeat: Repeat-Dose Study Adds Validation to RaniPill Platform
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Repeat-Dose Data for RaniPill Expected in 4Q22; 3Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
On-Track for Ph1 Part 2 Repeat-Dose Results for RT-102 in Q4; Q3 Financials
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
New RaniPill Program to Treat Autoimmune Diseases; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
New RT-111 Program Adds to RaniPill''s Blockbuster Potential; Pipeline Updates
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Company: Rani Therapeutics Holdings, Inc.
Industry: Medical - Biomedical and Genetics
Positive Part 1 Results from Ph1 Trial for RT-102 Osteoporosis; Q2 Financials
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A